| Metric | Q2'26 | Q3'26 | Change |
|---|---|---|---|
| Revenue (core YoY) | $1.83 B, +6.3% YoY | $1.88 B, +7.3% YoY | +5 bps acceleration |
| Operating margin ex‑tariff | 26.4% | 27.2% | +80 bps expansion |
| Gross margin ex‑tariff | 55.0% | 54.9% | -10 bps dip |
| EPS (ex‑tariff) | $1.49 | $1.56 | +7 cents (+5%) |
| Operating cash flow | $277 M | $519 M | +88% surge |
| CapEx | $76 M | $80 M | +5% increase |
| Net leverage | 0.7× | 1.0× | Leverage up but still modest |
| Book‑to‑bill | ≈1.0 (Q2) | >1.0 for 10th straight quarter | Continues strong order flow |
| Advanced Therapeutics (CDMO) growth | High‑single‑digit Q2 | ≈30% Q3 | Accelerated specialty CDMO growth |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.